Pfizer’s $11 Billion Cancer-Drug Deal Takes Pricey Path to Growth
The Pfizer Inc. company logo is seen on packaging for Viagra tablets, produced by Pfizer Inc., in this arranged photograph taken in London, U.K. (Photographer: Chris Ratcliffe/Bloomberg)  

Pfizer’s $11 Billion Cancer-Drug Deal Takes Pricey Path to Growth

BloombergOpinion
Bookmark
(Bloomberg Opinion) -- Pfizer Inc. is demonstrating once again how expensive it is for pharma firms to buy their way to growth.
BQ Install

Bloomberg Quint

Add BloombergQuint App to Home screen.